Compare Inovio Pharmaceuticals Inc (INO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Koninklijke Philips NV — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 209.6× Inovio Pharmaceuticals Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Koninklijke Philips NV for 84 Days on average.
| INO | PHG | |
|---|---|---|
Market Cap | $112.19M | $23.52B |
Volume | 3,201,278 | 1,635,069 |
Sector | Health | Health |
52-Week High | $2.65 | $32.91 |
52-Week Low | $0.66 | $23.81 |
Typical Hold Time | 43 Days | 84 Days |
Enterprise Value | $83.51M | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
PHG trades at $24.30, up 0.87% with a bearish technical signal despite three consecutive quarterly earnings beats. The company shows improving fundamentals with net income turning positive at $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care.
While analyst consensus leans Hold (63.64%), the improving profitability trajectory and reasonable valuation (P/E 18.94) present opportunity, though technical weakness and competitive healthcare market risks require monitoring. The stock faces resistance near $25 with support at $24, with institutional ownership showing mixed signals through recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
